Circulating fibroblast growth factor 21 (FGF21) as diagnostic and prognostic biomarker in renal cancer.

KNOTT, ME; PASIK, L; GUEGLIO, O; GUADALUPE PALLOTTA; RANUNCOLO, SM; NUÑEZ, M; PURICELLI, LI; DE LORENZO, MS

Phyladelphia

Congreso; 107th Annual Meeting of the American Association for Cancer Research (AACR); 2016

American Association for Cancer Research (AACR)

AbstractBackground: The finding of new biomarkers is needed to have a better sub-classification of primary renaltumors (RCC) as well as more reliable predictors of outcome and therapy response. In this study, we evaluated therole of circulating FGF21, an endocrine factor, as a diagnostic and prognostic biomarker for ccRCC.Materials and Methods: Serum samples from healthy controls (HC), clear cell and chromophobe RCC cancerpatients were obtained from the serum biobank ?Biobanco Público de Muestras Séricas Oncológicas? (BPMSO)of the ?Instituto de Oncología ?Ángel H. Roffo?. Serum FGF21 and leptin were measured by ELISA while othermetabolic markers were measured following routinely clinical procedures.Results: One of our major findings was that FGF21 levels were significantly increased in ccRCC patientscompared with HC. Moreover, we showed an association between the increased serum FGF21 levels and theshorter disease free survival in a cohort of 98 ccRCC patients, after adjustment for other predictors of outcome.Conclusion: Our results suggest that higher FGF21 serum level is an independent prognostic biomarker,associated with worse free-disease survival.